Category list : All-Wales Medicines Strategy Group
Sort by: Newest first Oldest first A-Z Z-A
-
Dolutegravir approved in Wales Subscription
Dolutegravir, in combination with other antiretrovirals, has been approved for use in NHS Wales by the All Wales Medicines Strategy Group to treat HIV infection in those aged 12 years and over.
-
Abraxane funded in Wales Subscription
Patients with metastatic pancreatic cancer in Wales will have access to the drug Abraxane (paclitaxel; Celgene) on the NHS following a positive decision from the All Wales Medicines Strategy Group in September 2014. Wales is the only country in the UK where the chemotherapy drug will be routinely available to eligible patients on the NHS.
-
Cannabinoid Sativex approved in Wales to treat MS symptoms
Wales has become the first country in the UK to approve the use of Sativex on the NHS to treat symptoms of multiple sclerosis.
-
AWMSG decisions Subscription
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Aripiprazole prolonged release injection as maintenance treatment for schizophrenia in adults stabilised on oral aripiprazole Azithromycin infusion to treat community-acquired pneumonia where parenteral therapy is necessary (however, it should not be used to treat pelvic inflammatory disease) Delta-9-tetrahydrocannabinol (Sativex; GW Pharma) ...
-
AWMSG decisions Subscription
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): eltrombopag to treat thrombocytopenia in adults with hepatitis C infection where the degree of thrombocytopenia is compromising the efficacy of interferon; imatinib for adjuvent treatment of KIT-positive gastrointestinal stromal tumours; Eviplera (emtricitabine, rilpivirine and tenofovir; Gilead) for treatment-experienced adults infected with HIV type 1; and velaglucerase ...
-
All Wales Medicines Strategy Group Subscription
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group: Tocilizumab for juvenile idiopathic polyarthritis (rheumatoid factor positive or negative and extended oligoarthritis) in patients aged 2 years and older; Inhaled indacaterol/glycopyrronium as a maintenance bronchodilator in adults with chronic obstructive pulmonary disease; Tenofovir disoproxil film-coated tablets and granules to treat chronic hepatitis B in adults whose disease ...
-
Revlar Ellipta approved for NHS use in Wales
Inhaled fluticasone furoate and vilanterol (Relvar Ellipta) has been approved for use in NHS Wales by the All-Wales Medicines Strategy Group (AWMSG). it is recommended as an option for symptomatic treatment of adults with chronic obstructive pulmonary disease.
-
New constipation drug gets a lukewarm response from DTB
Little published data on lubiprostone made it difficult to assess its efficacy, says the DTB
-
Atomoxetine, abatacept, linaclotide and nalmefene recommended for use in Wales
The All-Wales Medicines Strategy Group has endorsed atomoxetine, abatacept, linaclotide and nalmefene for use in NHS Wales in its latest round of medicines appraisals.
- Previous Page
- 1
- 2
- 3
- Next Page
Show 10 per page20 per page50 per page
